Devia A, Murray K A, Nelson E W
Department of Surgery, University of Utah School of Medicine, Salt Lake City, USA.
Arch Surg. 1997 May;132(5):512-5; discussion 515-7. doi: 10.1001/archsurg.1997.01430290058009.
To evaluate the influence of stereotactic core needle biopsy (SCNB) as an alternative to wire localization biopsy (WLB) on the evaluation and workup of nonpalpable mammographic lesions.
A 4-year retrospective clinical review.
University hospital and clinics.
All patients evaluated for nonpalpable mammographic lesions after screening, diagnostic mammography, or both during the 4-year period of the study were included.
Changes in the number and types of mammograms and diagnostic biopsies and the histologic findings using each technique (SCNB vs WLB), including total number of cancers diagnosed.
The number of screening mammograms and WLBs performed remained constant compared with a marked increase in the number of diagnostic mammograms and SCNBs. The rates of positive findings for each biopsy technique were consistent while the total number of cancers diagnosed increased dramatically. The percentage of biopsy specimens with positive results (ductal carcinoma in situ and invasive cancers) for SCNB was 13.3% compared with 26.2% for WLB specimens. There has also been an increase in the number of cancers found, from 22 in the first year to 54 in the fourth year. In the first year, 45% of these cancers were diagnosed by SCNB; in the fourth year, 83% of the cancers were diagnosed by SCNB.
Stereotactic core needle biopsy has replaced WLB as the standard for the diagnostic biopsy of suspicious, nonpalpable mammographic lesions. Since adopting this technique, more patients have been examined and their conditions diagnosed as breast cancer in an efficient, cost-effective manner.
评估立体定向粗针活检(SCNB)作为线定位活检(WLB)的替代方法对不可触及乳腺钼靶病变评估和检查的影响。
一项为期4年的回顾性临床研究。
大学医院及诊所。
纳入在研究的4年期间,经筛查、诊断性乳腺钼靶检查或两者均进行后,对不可触及乳腺钼靶病变进行评估的所有患者。
乳腺钼靶检查和诊断性活检的数量及类型变化,以及使用每种技术(SCNB与WLB)的组织学检查结果,包括确诊癌症的总数。
与诊断性乳腺钼靶检查和SCNB数量显著增加相比,筛查性乳腺钼靶检查和WLB的执行数量保持不变。每种活检技术的阳性发现率一致,而确诊癌症的总数大幅增加。SCNB活检标本阳性结果(导管原位癌和浸润性癌)的百分比为13.3%,而WLB标本为26.2%。发现的癌症数量也有所增加,从第一年的22例增加到第四年的54例。第一年,这些癌症中有45%通过SCNB诊断;第四年,83%的癌症通过SCNB诊断。
立体定向粗针活检已取代WLB,成为可疑的、不可触及乳腺钼靶病变诊断性活检的标准。自采用该技术以来,已对更多患者进行了检查,并以高效、经济有效的方式将其病情诊断为乳腺癌。